Please login to the form below

Not currently logged in
Email:
Password:

Rajesh Chopra joins board of e-Therapeutics

VP of translational and early drug development at Celgene joins as e-Therapeutics prepares to advance several investigational drugs into clinical trials

Dr Rajesh Chopra is to join the board of e-Therapeutics as a non-executive director.

He serves as VP of translational and early drug development at Celgene and joins UK-based drug discovery and development company e-Therapeutics as it prepares to advance several investigational drugs into clinical trials.

Prior to his current role at Celgene, where he is leading efforts to integrate drug discovery and clinical development at Celgene sites in the US and Europe, Chopra spent five years at AstraZeneca (AZ).

During his time at AZ he eventually held the role of medical science director, senior principal scientist and disease area team leader for blood cancers.

Chopra has also held positions outside pharma, working as a clinician and academic in the UK, and spent seven years as clinical director of the Department of Haematological Oncology at the Christie Hospital in Manchester. He is also a a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK.

Professor Oliver James, chair of e-Therapeutics, said: “Rajesh's appointment represents a further significant strengthening of our Board. He brings highly relevant senior-level experience gained in world-leading pharma and biotech companies and substantial expertise in oncology.

“His input will be of great value as we advance our clinical programmes and bring more new drugs through into development from our discovery operation.”

7th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...